Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care cung cấp cho các bạn kiến thức về ngành y đề tài: Combination therapy versus monotherapy: a randomised pilot study on the evolution of inflammatory parameters after ventilator associated pneumonia [ISRCTN31976779]. | Available online http content 10 2 R52 Research Combination therapy versus monotherapy a randomised pilot study on the evolution of inflammatory parameters after ventilator associated pneumonia ISRCTN31976779 Pierre Damas Christophe Garweg Mehran Monchi Monique Nys Jean-Luc Canivet Didier Ledoux and Jean-Charles Preiser Department of General Intensive Care University Hospital Centre Domaine universitaire du Sart-Tilman B-4000 Liege Belgium Corresponding author Pierre Damas pdamas@ Received 11 Jan 2006 Revisions requested 30 Jan 2006 Revisions received 17 Feb 2006 Accepted 6 Mar 2006 Published 28 Mar 2006 Critical Care 2006 10 R52 doi cc4879 This article is online at http content 10 2 R52 2006 Damas et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Open Access Abstract Introduction Combination antibiotic therapy for ventilator associated pneumonia VAP is often used to broaden the spectrum of activity of empirical treatment. The relevance of such synergy is commonly supposed but poorly supported. The aim of the present study was to compare the clinical outcome and the course of biological variables in patients treated for a VAP using a monotherapy with a beta-lactam versus a combination therapy. Methods Patients with VAP were prospectively randomised to receive either cefepime alone or cefepime in association with amikacin or levofloxacin. Clinical and inflammatory parameters were measured on the day of inclusion and thereafter. Results Seventy-four mechanically ventilated patients meeting clinical criteria for VAP were enrolled in the study. VAP was mierobiologieally confirmed in 59 patients 84 . Patients were randomised to receive cefepime C group 20 patients cefepime with .
